INCR
InterCure Ltd.
5.40$
+1.9%
vs. previous close
Closing price · As of: Oct 1, 2026
Statements
Income Statement
All figures as the change versus the prior period, in percent. Periods without a positive comparison base stay empty.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q1 24 | Q2 24 | Q3 24 | Q1 25 | Q2 25 | Q3 25 | Q1 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | +5.0% | +0.5% | -3.5% | -28.3% | -14.4% | +0.0% | -10.0% | +14.9% | +0.0% | +7.8% | +0.0% | – | |
| – | +46.7% | -9.9% | -2.9% | -20.8% | -24.0% | +0.0% | +34.1% | -20.3% | +0.0% | +55.6% | +0.0% | – | |
| – | -44.0% | +32.7% | -4.9% | -44.4% | +14.7% | +0.0% | -99.1% | +10,187.2% | +0.0% | -98.8% | +0.0% | – | |
| – | +45.0% | -9.8% | -36.9% | -33.3% | +65.9% | +0.0% | -11.0% | -2.1% | +0.0% | +4.2% | +0.0% | – | |
| – | +317.4% | -78.4% | -8.1% | -9.5% | -9.2% | +0.0% | +93.5% | -58.8% | +0.0% | +85.2% | +0.0% | – | |
| – | -11.1% | +3.5% | -8.7% | +119.9% | -72.7% | +0.0% | +150.8% | -55.8% | +0.0% | -3.1% | +0.0% | – | |
| – | -109.7% | – | -2.1% | -558.2% | – | +0.0% | -839.2% | – | +0.0% | -676.6% | – | – | |
| – | -4.6% | +36.1% | +7.5% | – | – | +0.0% | -1.5% | -10.0% | +0.0% | +26.0% | +0.0% | – | |
| – | -173.0% | – | -77.3% | -7,973.7% | – | +0.0% | -6,124.2% | – | – | – | – | – | |
| – | -484.5% | – | -297.5% | – | -61.9% | +0.0% | -1,181.8% | – | – | – | – | – | |
| – | -27.4% | -95.9% | +2,181.8% | -786.6% | – | +0.0% | -4,931.0% | – | – | – | – | – | |
| – | -131.9% | – | -15.4% | -152.9% | – | +0.0% | -753.3% | – | +0.0% | -588.4% | – | – |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 1, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.